What are the Advantages of Xarelto® for Protecting Your Patients with Comorbidities?
Stroke Prevention in Non-Valvular Atrial Fibrillation
Xarelto is indicated for stroke prevention in adults with non-valvular atrial fibrillation with one or more risk factors1
Confidently Prevent Critical Events, Even in High-Risk Patients2
Avoid the most critical events as you reach your treatment goals2
Xarelto gives your patients the highly effective protection they need2
ap value for superiority.
Xarelto can help you avoid the most critical events as you reach your treatment goalsb,2
ap value for superiority. bThe RRR was calculated as 1–HR by Bayer. Stroke or systemic embolism: HR 0.79 (0.65–0.95), critical organ bleeding: HR 0.69 (0.53–0.91), intracranial haemorrhage: HR 0.67 (0.47–0.93), fatal bleeding: HR 0.50 (0.31–0.79).
Protection established in patients with a high bleeding risk3
cTrial was not powered to definitively establish either superiority or non-inferiority.
Study powered for non-inferiority for primary endpoint of stroke or systemic embolism vs warfarin. No significant difference in primary safety endpoint of major or clinically relevant non-major bleeding vs warfarin.2
Robust Evidence in Patients with the Highest Risk of Bleeding1
The pivotal clinical trial for Xarelto has the most patients with the highest HAS-BLED scores1
62% of patients in ROCKET AF had a very high risk of bleeding1
Real World Safety that Reflects the Patients You see Every Day4
Data from the real world that complements clinical evidence4
In XANTUS POOLED:4
Prospective international phase IV real world study with independent event adjudication
Mean CHADS2-score: 2.0
Xarelto 15 mg OD Provides an Evidence-Based Choice for Your Patients with Renal Impairment5
Reassuring evidence for a reduced dose that was specifically tested for this high-risk group of patients5
Robust evidence for Xarelto 15 mg OD in patients with renal impairment2,5
The circle represents 100% of the total Xarelto study population in the trial.
dRenal impairment defined as CrCl 30–49 ml/min.
Xarelto 15 mg OD provides an evidence-based choice for your patients with renal impairment5
Xarelto 15 mg once daily: For patients with NVAF
and CrCl 30–49 ml/min. With caution in patients with CrCl 15–29 ml/min. Use is not recommended in patients with CrCl <15 ml/min.6
ePrimary efficacy endpoint: composite of all stroke (both ischaemic and haemorrhagic) and systemic embolism.
Significant stroke reduction with a consistent safety profile in NVAF patients with worsening renal function7
Worsening renal function was defined as a decrease of >20% from screening creatinine clearance measurement at any time point during the study7
Convenient and Simple Dosing for NVAF Patients6,2,3,5
Xarelto can be used in patients with different levels of renal impairment6,2,5
Xarelto can be used in patients with different levels of renal impairmentf,6,2,5
fXarelto 10 mg can be taken with or without food. Xarelto 15/20 mg is to be taken with food.6 gPlus P2Y12 inhibitor. hCrCl 15–29 ml/min – To be used with caution. CrCl <15 ml/min – Use not recommended.
OD, once daily; NVAF
, non-valvular atrial fibrillation; AF
, atrial fibrillation; RRR
, relative risk reduction; ARR, absolute risk reduction; YR
, year; PCI, percutaneous coronary intervention; NNT, numbers needed to treat; GI
, gastrointestinal; CrCl, creatinine clearance; NMCR, non-major clinically relevant; HR
, hazard ratio.
HAS-BLED score is used to estimate major bleeding risk in patients with NVAF. CHADS2-score is used to estimate stroke risk in patients with NVAF.